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Abstract
Immunity and inflammatory pathways are important in the genesis of non-melanoma skin cancers (NMSC). Functional
genetic variation in immune modulators has the potential to affect disease etiology. We investigated associations between
common variants in two key regulators, MIR146A and RNASEL, and their relation to NMSCs. Using a large population-based
case-control study of basal cell (BCC) and squamous cell carcinoma (SCC), we investigated the impact of MIR146A SNP
rs2910164 on cancer risk, and interaction with a SNP in one of its putative targets (RNASEL, rs486907). To examine
associations between genotype and BCC and SCC, occurrence odds ratios (OR) and 95% confidence intervals (95%CI) were
calculated using unconditional logistic regression, accounting for multiple confounding factors. We did not observe an
overall change in the odds ratios for SCC or BCC among individuals carrying either of the RNASEL or MIR146A variants
compared with those who were wild type at these loci. However, there was a sex-specific association between BCC and
MIR146A in women (ORGC = 0.73, [95%CI = 0.52–1.03]; ORCC = 0.29, [95% CI = 0.14–0.61], p-trend,0.001), and a reduction in
risk, albeit not statistically significant, associated with RNASEL and SCC in men (ORAG = 0.88, [95%CI = 0.65–1.19]; ORAA = 0.68,
[95%CI = 0.43–1.08], p-trend = 0.10). Most striking was the strong interaction between the two genes. Among individuals
carrying variant alleles of both rs2910164 and rs486907, we observed inverse relationships with SCC (ORSCC = 0.56,
[95%CI = 0.38–0.81], p-interaction = 0.012) and BCC (ORBCC = 0.57, [95%CI = 0.40–0.80], p-interaction = 0.005). Our results
suggest that genetic variation in immune and inflammatory regulators may influence susceptibility to NMSC, and novel
SNP-SNP interaction for a microRNA and its target. These data suggest that RNASEL, an enzyme involved in RNA turnover, is
controlled by miR-146a and may be important in NMSC etiology.
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Introduction
Non-melanoma skin cancers (NMSC) are the most prevalent
malignancy in the US, exceeding all other cancers combined with
an estimated 2 million new diagnoses each year [1,2]. Incidence of
NMSC, which include basal cell (BCC) and squamous cell
carcinomas (SCC), has continued to rise. Both BCC and SCC
are relatively treatable and have low rates of mortality, but
NMSCs can have high rates of recurrence and can cause
significant disfiguration, particularly on the head and neck regions
where they commonly occur [2–4]. While BCC and SCC both
arise from keratinocytes or their precursors, there are key
differences in their incidence and etiology. BCC tends to be more
common and is thought arise de novo, while SCC develops in a
multistep progression from premalignant precursor lesions to more
aggressive skin tumors over time [2–4]. SCC also appears to be
more strongly related to cumulative lifetime sun exposure and has
a greater capacity to metastasize [5]. NMSCs are generally not
included in cancer registries, making large epidemiological studies
challenging.
While ultraviolet light exposure and skin sensitivity are known
risk factors for NMSC development, inflammation and immunity
are also key elements of NMSC etiology. Immunosuppressed
individuals tend to have much higher NMSC incidence rates than
immunocompetent individuals, as evidenced by 65- to 250-fold
increased incidence rates of SCC and 10- to 16-fold increased
incidence rates of BCC in organ transplant recipients who are
routinely treated with immunosuppressive agents to prevent organ
rejection, and a more modest increase in NMSC incidence among
individuals chronically treated with glucocorticoids [6–9]. Further,
imiquimod, a topical cream that is thought to induce a localized
immune response, has been a successful treatment for NMSC and
precancerous skin lesions [10]. Given that immune function has
been closely linked to NMSC development, it is likely that genetic
variation in key immune regulatory mechanisms impacts suscep-
tibility to these prevalent malignancies.
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e93602
MiR-146a is a microRNA (miRNA) of particular interest in the
etiology NMSCs, as it is an important modulator of inflammatory
immune responses, coordinating myeloid and lymphocyte function
to impact aspects of both innate and adaptive immunity [11].
MiRNAs are short, non-coding RNAs that repress specific target
mRNAs by binding imperfectly to sequences frequently located in
39-untranslated regions (UTR), and have emerged as key
regulators of virtually all cellular processes, both physiological
and pathogenic. Post-transcriptional regulation by miRNAs is
thought to affect the majority of mRNA transcripts and functional
genetic variation in miRNAs has the potential to broadly impact
disease processes, given the large number of genes and pathways
targeted by each miRNA. However, there are only a few examples
of functional polymorphisms in miRNAs. Among them is
rs2910164 contained in the pre-miR-146a, which reduces miR-
146a abundance, in turn altering the cellular transcriptome and
increasing levels of its targets [12,13]. rs2910164 may play a role in
certain inflammatory conditions, such as rheumatoid arthritis and
inflammatory bowel disease, and has been shown to increase
susceptibility to hepatocellular carcinoma, and thyroid cancer
[12,14–16].
MiR-146a has 224 potential mRNA binding targets, including
the cancer susceptibility gene RNASEL [17]. Ribonuclease L
(RNASEL) is an interferon-activated ribonuclease, which degrades
cellular and viral RNA upon activation. This activity is critical to
cellular defense against viral infection, by limiting viral propaga-
tion and inducing apoptosis in infected cells, prior to a full immune
response [18]. RNASEL is maintained at very low levels in the cell
and its regulation is unclear, but may include miRNA suppression
of its transcript and targeting of RNASEL by a miRNA, such as
miR-146a, would serve to reduce cellular RNASEL levels [19,20].
The RNASEL rs486907 Arg to Gln variant has 3-fold reduced
enzyme activity, which could enhance virus susceptibility, diminish
control of cellular RNA levels, impair the cellular stress response,
or induce apoptosis [21]. While under normal conditions
RNASEL has tumor suppressive and anti-proliferative functions,
RNASEL variants, including the common rs486907 variant, have
been associated with risk of a number of cancers, i.e. prostate,
colorectal and pancreatic cancer, and overall risk of cancer in
individuals of African descent [21–32].
To examine the effect of genetic variation in key immune
components on NMSC susceptibility. we investigated the impact
of the MIR146A SNP rs2910164 on NMSC risk, and potential
interaction with one of its putative targets RNASEL (rs486907) as
part of a large population-based, case-control study of BCC and
SCC in New Hampshire.
Materials and Methods
Ethics Statement
All study protocols and materials were approved by the
Dartmouth College Institutional Review Board (federal assurance
number 00003095). All participants provided written, informed
consent at the time of enrollment. All consent procedures and
materials were approved by the Dartmouth College Institutional
Review Board in accordance with the Committee for the
Protection of Human Subjects at Dartmouth College.
Study Population
Study subjects included those described in our earlier reports
[33–36]. Briefly, to identify cases we enlisted the collaboration of
dermatologists and pathology laboratories throughout New
Hampshire and bordering regions [34]. Newly diagnosed cases
of histologically confirmed BCC and SCC in New Hampshire
were identified from July 1, 1993 to June 30, 1995 in the initial
enrollment phase and July 1, 1997 to March 30, 2000 in the
second enrollment phase. Eligible subjects included New Hamp-
shire residents who, at the time of diagnosis, 1) were between 25
and 74 years of age, 2) had a listed telephone number and 3) spoke
English. The BCC cases were randomly sampled in order to
ensure representativeness of age, sex, and anatomic site for all
incident BCCs within New Hampshire. We identified 1084
potential participants. Of these caess, we contacted and confirmed
the eligibility on 1036 (96%), of whom 80% agreed to participate.
Individuals with lesions on genital sites were excluded due to likely
differences in etiology.
Controls aged 25–64 years were identified from the New
Hampshire State Department of Transportation files and those
aged 65–74 years were obtained from enrollment lists from the
Center for Medicaid and Medicare Services. Potential controls
were frequency-matched on age (25–34, 35–44, 45–54, 55–64,
65–69 and 70–74 years) and gender to the combined distribution
of case groups (roughly a two to one ratio to cases in the first phase
and one to one ratio in the second phase) [33,34]. As with cases,
controls were required to speak English and to have a listed
telephone number. For interviewing purposes, controls were
randomly assigned reference dates corresponding to the cases’
diagnosis dates. Of the 1527 potential controls, 1462 (96%) were
contacted and confirmed as eligible, and 1066 (73%) of those were
interviewed.
Personal Interview
Study participants completed a structured personal interview,
usually at their homes. To minimize reporting bias, we did not
reveal the specific hypotheses of interest to either the interviewer
or participant, and did not inform the interviewers of the case-
control status of participants. The interview included sociodemo-
graphic information (level of education), tobacco use, prolonged
use of glucocorticoid drugs (for one month or longer) and reasons
for use, assessment of pigmentary characteristics and nevi, and
questions relating to skin sensitivity to the sun and sun exposure
using a standardized instrument developed for a case-control study
conducted in Australia [37,38].
Genotyping
We collected a venous blood sample (20–30 ml) in heparinized
tubes and separated plasma, white blood cells and red blood cells
by centrifugation at 3000 rpm for 20 min at 4uC. Cells were
washed twice in saline, aliquoted and stored at 280uC until
analysis. Each specimen was labeled and given a unique identifier
that did not reveal the subject’s case-control status. DNA was
extracted using Qiagen Genomic DNA extraction kits (Valencia,
CA). For quality assurance purposes, 10% of blood and buccal
samples were used as integrated duplicates. Genotyping for the
MIR146A SNP (rs2910164) was done using an allelic discrimina-
tion assay. The RNASEL SNP (rs486907) was genotyped at the
University of Minnesota Biomedical Genomics Center using the
Sequenom platform.
Statistical Analysis
We classified cases according to their status as of the date of
their first skin cancer diagnosed during the study period, or for
controls, as of their reference date. This subject classification plan
results in relative risk estimates of incidence density ratios [39]. We
examined risk of both BCC and SCC according to MIR146A and
RNASEL genotypes, in comparison to control subjects. We
examined the main effects for each genotype, as well as the
statistical interaction between the genotypes, computing the
SNP-SNP Interaction in Non-Melanoma Skin Cancer
PLOS ONE | www.plosone.org 2 April 2014 | Volume 9 | Issue 4 | e93602
adjusted odds ratios (OR) and 95% confidence intervals (CI) of
SCC and BCC associated with MIR146A and RNASEL genotypes.
In each of these analyses, we used unconditional logistic
regression, taking into account multiple confounding factors
[40]. These covariates included age at diagnosis, sex (except in
analyses stratified by sex), level of education, skin sensitivity to the
sun, and lifetime number of painful sunburns. Analyses of SCC
additionally included adjustment for cigarette smoking status
1 year before the reference date, as smoking been found to
increase risk of SCC, but not BCC [41]. Statistical analyses were
conducted with SAS 9.2 (SAS Institute, Cary, NC). All P values
are two sided.
Results
Our study included 920 BCC cases, 682 SCC cases, and 824
controls, with men comprising the majority of all groups (Table 1).
The mean age of our study population was 61.4 years. More than
two-thirds of participants were current or former smokers
(n = 1524), with BCC cases more likely to be never smokers
(p = 0.002) than controls. Approximately half of all participants
(n = 1164) indicated having three or more severe sunburns in their
lifetime, with greater number of lifetime sunburns reported among
both BCC and SCC cases, as compared to controls (BCC: p,
0.001, SCC: p,0.001). Greater skin sensitivity, as indicated by
tendency to burn, was also reported more frequently for both BCC
(p,0.001) and SCC (p,0.001), as compared to controls.
Main Effects
We first tested the independent associations of RNASEL
(rs486907) and MIR146A (rs2910164) with risk of SCC or BCC
(Table 2). More than half of all participants carried at least one
copy of the RNASEL variant A-allele, while the MIR146A variant
C-allele was less common and present in approximately one-third
of participants. We did not observe an overall increase or decrease
in the ORs for SCC or BCC among individuals carrying either of
the RNASEL or MIR146A variants compared with those who were
wild type at these loci. However, in an analysis of main effects
stratified by sex, women who carried theMIR146A variant C-allele
had a reduced odds ratio for BCC (ORGC=0.73, [95%
CI= 0.52–1.03]; ORCC=0.29, [95% CI= 0.14–0.61], p for trend
,0.001), but the association was not observed in men (Table 3).
Additionally, we observed lower, but not statistically significant,
odds ratios for SCC for men carrying the RNASEL variant A- allele
(ORAG= 0.88, [95% CI= 0.65–1.19]; ORAA= 0.68, [95%
CI= 0.43–1.08], p for trend= 0.10) compared to men who were
wild type; but this was not observed in women (Table 3).
Gene-gene Interaction Effects
We then assessed whether the presence of both variants
influenced the risk of BCC or SCC (Table 4). Among those wild
type for MIR146A, we did not observe a change in risk for
individuals who carried a RNASEL variant A-allele
(ORBCC= 1.07, [95% CI= 0.82–1.41]; ORSCC=1.02, [95%
CI= 0.75–1.39]), when compared to those that were wild type,
whereas, among those who carried a MIR146A variant C-allele,
those with a variant allele of in RNASEL had reduced odds of both
BCC (OR=0.57, [95% CI= 0.40–0.80], p for interaction= 0.005)
and SCC (OR=0.56, [95% CI= 0.38–0.81], p for interac-
tion= 0.012), when compared to those who were wild type for
RNASEL.
Discussion
In our population-based, case-control study of BCC and SCC,
we found evidence of interacting effects of common variants in two
genes involved in aspects of inflammation and immunity, RNASEL
and MIR146A, on risk of NMSCs. While neither of these variants
appeared to affect risk of BCC or SCC when considered singly in
the entire population, gender-specific associations were observed,
i.e. significant reduction in risk of BCC in women who carried the
MIR146A variant C-allele, and a borderline reduction in risk of
SCC in men who carried the RNASEL variant A-allele. This is
consistent with our prior work indicating gender-specific immu-
nogenetic risk effects for NMSCs, which reported that while skin
type and lifetime number of sunburns were important risk factors
for SCC and BCC in both men and women, the relative
contribution of genetic variants involved in UV-induced immu-
nosuppression to risk of SCC and BCC vary by sex [42,43].
The rs486907 RNASEL variant has been associated with
increased risk of several cancers [21,25–32]. This Arg to Gln
variant has been shown to inhibit dimerization of RNASEL into its
active form, resulting in a 3-fold reduction in enzyme activity that
strongly affects its endonuclease capacity and thus its pro-apoptotic
activity [21]. However, there are inconsistencies across studies
with regard to risk direction for rs486907. Studies of sporadic
prostate cancers have shown that the variant A allele of rs486907
may be associated with lower grade tumors, as assessed by Gleason
score [28,44]. It is possible that the reduction in activity associated
with rs486907 may have differential effects in various tissue
contexts, including tumor types, and when found in combination
with other genetic variants, such as MIR146A rs2910164.
RNASEL plays a significant role in viral clearance and it has
been suggested that variation in RNASEL may alter risk of viral-
associated cancers, such as head and neck squamous cell
carcinoma and cervical cancer, as well as non-viral cancers such
as breast cancer [45,46]. Discrepancies between large studies of
hereditary prostate cancer suggest that environmental factors, such
as viral infection, may modulate the impact of RNASEL variation
on carcinogenesis [18]. Indeed, viral infection with xenotropic
murine leukemia virus-related virus (XMRV) has been observed to
be more common in prostate cancers of individuals homozygous
for the RNASEL rs486907 variant [47]. While RNASEL may be a
more general marker of cancer risk, it is possible that RNASEL
variants could also impact viral susceptibility, thus increasing the
risk of developing a persistent infection with potentially oncogenic
viruses such as human papillomavirus (HPV). As cutaneous HPVs
have been previously associated with incidence of SCC, a future
area of inquiry would be to examine this relationship according to
RNASEL genotypes in our study population [48–51].
The immune system imposes highly regulated multi-level
controls upon its responses to pathogen and miR-146a plays a
key role in modulating these functions. While the inflammatory
response is essential for clearing pathogenic infection, it must be
tightly regulated–a role that is fulfilled in part by miR-146a in
response to TLR4 activation [52]. As demonstrated in MIR146A
knockout mice, miR-146a impacts both innate and adaptive
immunity, with loss of miR-146a leading to hyper-responsiveness
to LPS challenge, an activated T-cell phenotype, an overabun-
dance of pro-inflammatory cytokines, and eventually to hemato-
poietic malignancy [53]. Interestingly, the heightened immune
response characteristic of miR-146a knockout mice makes them
more resistant to bacterial infection than wild-type animals [54].
MIR146A transcription is induced by the pro-inflammatory
immune response and NF-kB activation and in turn, miR-146a
targets NF-kB signaling component IRAK-1 and TRAF, creating
SNP-SNP Interaction in Non-Melanoma Skin Cancer
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a negative feedback loop to downregulate the immune response
and preventing inflammatory damage [55]. In other words,
inefficient binding of miR-146a to its targets in the NF-kB
signaling pathway, such as IRAK-1, or diminished endogenous
levels of miR-146a can both promote immune overactivation and
inflammation [11,56,57]. Such effects have been shown to occur in
the presence of rs2910164, which leads to diminished levels of
mature miR-146a, which in turn relieves the inhibition of its
targets in the cell [12,13]. Therefore, the MIR146A rs2910164
variant would be hypothesized to impact the immune system by
increasing immune hyper-responsiveness.
As a key regulator of inflammation, it is not surprising that
MIR146A variation has also been implicated in oncogenesis and
vascular endothelial activation, as well as other inflammatory and
autoimmune diseases, including rheumatoid arthritis, psoriatic
arthritis and systemic lupus erythematosus (SLE) [52,56–59].
Specifically, rs2910164 has been associated with increased
incidence of thyroid tumors [12,13,16]. A recent study in a
Hungarian population found an association between rs2910164
and increased susceptibility to head and neck squamous cell
carcinoma [60]. Others have reported similar associations between
rs2910164 and cancers of the prostate, cervix, breast and digestive
tract [15,61–64]. However, a small body of work has begun to
show that rs2910164 may be protective in some populations and in
specific cancer types. One case-control study found that the
rs2910164 variant actually reduced risk of colorectal cancer in a
Chinese population [65]. A meta-analysis of 29 studies showed
significantly lower cancer risks among Asians associated with
rs2910164, while a tumor-type subgroup analysis showed that the
rs2910164 C allele associated with decreased risk of hepatocellular
Table 1. Characteristics of Participants in New Hampshire Skin Study*.
N (%) or mean
Variable Overall Control BCC SCC
Sex
Men 1459 504 (34.5) 518 (35.5) 437 (30.0)
Women 967 320 (33.1) 402 (41.6) 245 (25.3)
Age (years)
Mean 61.4 61.6 59.1 64.2
25–34 26 5 (19.2) 18 (69.2) 3 (11.5)
35–49 345 115 (33.3) 181 (52.5) 49 (14.2)
50–54 205 56 (27.3) 102 (49.8) 47 (22.9)
55–59 289 103 (35.6) 111 (38.4) 75 (26.0)
60–64 356 115 (32.3) 142 (39.9) 99 (27.8)
65–69 587 238 (40.6) 171 (29.1) 178 (30.3)
70–74 618 192 (31.1) 195 (31.6) 231 (37.4)
Education
High School, GED or
technical school
1005 388 (38.6) 331 (33.0) 286 (28.5)
College 839 265 (31.6) 340 (40.5) 234 (27.9)
Postgraduate School 580 171 (29.5) 247 (42.6) 162 (27.9)
Smoking
Never 901 285 (31.6) 393 (43.6) 223 (24.8)
Former 1169 409 (35.0) 405 (34.6) 355 (30.4)
Current 355 130 (36.6) 121 (34.1) 104 (29.3)
Skin Sensitivity{
Severe sunburn with
blistering
172 44 (25.6) 61 (35.5) 67 (39.0)
Painful sunburn
followed by peeling
773 202 (26.1) 329 (42.6) 242 (31.3)
Mild sunburn with
some tanning
1181 422 (35.7) 455 (38.5) 304 (25.4)
Tan without sunburn 297 155 (52.2) 75 (25.3) 67 (22.6)
Lifetime sunburns
None 660 266 (40.3) 225 (34.1) 169 (25.6)
1 to 2 576 233 (40.5) 198 (34.4) 145 (25.2)
3 or more 1164 316 (27.2) 489 (42.0) 359 (30.8)
*Numbers may not sum to the overall total due to missing data. Two individuals were missing education information, one was missing smoking, three were missing skin
sensitivity and twenty-six were missing information about lifetime sunburns. They were excluded from analyses.
{Sun sensitivity was defined as the reaction to 1 hour of sun exposure the first time in the summer.
doi:10.1371/journal.pone.0093602.t001
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carcinoma and cervical squamous cell carcinoma [66]. Another
meta-analysis reported that rs2910164 was associated with
reduced cancer risk in Caucasians, but with increased risks in
certain subgroups such as Asians, men, and smokers [67].
Similarly, it is possible that the underlying molecular phenotype
and etiology of SCC and BCC may impact the activity of these
immune regulatory SNPs, potentially accounting for risk reduction
that we observed for these tumor types in our study. Further work
is necessary to elucidate the specific factors that may additionally
influence disease risk in the context of rs2910164 genetic variation.
In this study, a decrease in risk of skin cancer was observed only
when both variants, rs486907 RNASEL and MIR146A rs2910164,
were present. RNASEL is a predicted target of miR-146a [17], but
currently, to our knowledge, direct evidence for miR-146a as a
transcriptional regulator of RNASEL mRNA is lacking. Future
work is needed to further clarify the regulatory relationship
between miR-146a and RNASEL. If RNASEL is indeed targeted
by miR-146a, the reduced levels of miR-146a due to the
rs2910164 variant allele would likely result in the production of
more of RNASEL, albeit in a less active form in the presence of
rs486907, as this variant produces a truncated form of RNASEL
with reduced functionality. In this scenario, one might predict a
decreased or unchanged risk of cancer. However, given our results
showing that the two variants together reduce NMSC risk, it is
more plausible that these two immune modulators might be acting
upon one another in a less direct manner and that the observed
reduction in skin cancer risk in our study may result from
independent changes that are predicted from each of these
variants (i.e. altered immune function or impaired apoptosis). In
this alternate scenario of an indirect relationship, the interaction
between miR-146a and RNASEL may not only be dependent upon
their expression levels, but also on the expression levels of other
miR-146a target transcripts. A reduction in RNASEL activity in
the presence of rs486907 would be predicted to increase
susceptibility to viruses and impair apoptosis, and ultimately
increase cellular stress and targeting by the immune system.
Concomitantly, the MIR146A rs2910164 variant likely alters
overall immune function and increases immune hyper-responsive-
ness. Little is known about how these two immune mediators may
impact one another in the context of NMSC, but it is possible that
the interaction between RNASEL and miR-146a might reflect the
interaction between important cell types in the cutaneous
epithelium, such as between T-cells, where miR-146a is critical
to suppressor function, and keratinocytes, where RNASEL may
play a role in viral defense or regulating the cellular stress
response. An individual’s immune response or surveillance may be
heightened in the presence of MIR146A rs2910164 and can better
target cells that are stressed due to altered RNA levels or that are
infected with a cutaneous virus, due to reduced RNASEL activity.
We observed some sex-specific differences in susceptibility,
including a significant reduction in risk of BCC in women who
carried the MIR146A variant C-allele, and a borderline reduction
in risk of SCC in men who carried the RNASEL variant A-allele.
We were unable to examine the SNP-SNP interaction for men and
women separately, due to sample size limitations. In previous
work, we observed sex differences in susceptibility to SCC and
BCC, in relation to other immune-related genetic variants [42,43].
Specifically, while common risk factors for SCC and BCC, such as
skin type and lifetime number of sunburns, were important in both
men and women, we found sex-specific differences in the relative
contribution of genetic variants involved in UV-induced immu-
nosuppression to risk of SCC and BCC [42,43]. It is possible that
estrogen could somehow play a role in these observed differences
in NMSC risk. Estrogen receptors, specifically estrogen receptor-b,
are expressed in human keratinocytes, and estrogen can impact
proliferation of keratinocytes, wound healing and vascularization
of skin [68]. Interestingly, interferon-stimulated exonuclease gene
20 kDa (ISG20), which is member of the 39 to 59 exonuclease
family that also includes RNASEL, can be induced by both
interferon and estrogen [69,70]. Although very speculative, one
could envision a mechanism in which it is possible that RNASEL
could also be dually-regulated by interferon and estrogen
signaling, providing a link between gender and the RNASEL SNP.
The strength of our study lies in its population-based, case-
control design, the large number of histologically confirmed cases
of SCC and BCC identified through a surveillance network of
Table 2. Main effects of RNASEL rs486907 and MIR146A rs2910164 genotypes on non-melanoma skin cancer risk.
BCC SCC
Controls N OR (95% CI)* N OR (95% CI)*
RNASEL
G/G 288 370 reference 258 reference
G/A 362 375 0.85 (0.68–1.06) 271 0.84 (0.66–1.07)
A/A 106 113 0.88 (0.64–1.21) 74 0.79 (0.56–1.13)
trend# 0.91 (0.79–1.06) 0.88 (0.74–1.04)
P for trend = 0.23 P for trend = 0.12
MIR146A
G/G 481 567 reference 388 reference
G/C 271 281 0.88 (0.71–1.10) 241 1.09 (0.87–1.38)
C/C 43 44 0.80 (0.51–1.26) 34 0.90 (0.55–1.48)
trend# 0.89 (0.75–1.05) 1.03 (0.85–1.23)
P for trend = 0.17 P for trend = 0.79
*Adjusted for age, sex, level of education, cigarette smoking status 1 year before the reference date (for SCC only), skin sensitivity (measured by skin reaction after
1 hour of sun exposure the first time in the summer) and the number of lifetime painful sunburns.
#Trend for any variant allele.
doi:10.1371/journal.pone.0093602.t002
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dermatologists, dermopathologists and pathologists, as well as the
availability of covariate data on lifestyle factors and skin
characteristics, such as sun exposure and skin sensitivity. While
this population-based design is representative of the general
population and less susceptible to selection bias than hospital and
clinic-based studies, we cannot rule out the possibility that non-
participation introduced selection bias or residual confounding
might exist. Further, our study has the potential for lack of
generalizability due to the fact that it is located at higher latitude
relative to other at-risk populations.
To our knowledge, our study is the first to examine the effects of
RNASEL and MIR146A genetic variants on non-melanoma skin
cancer susceptibility. Our findings suggest that polymorphisms in
these immune and inflammatory regulators may influence
susceptibility to non-melanoma skin cancers. Further, our work
is among the first to suggest a SNP-SNP interaction for a miRNA
and its target gene. These data imply that RNASEL, an enzyme
involved in cellular and viral RNA turnover, is controlled by miR-
146a and that this process may be important in skin cancer
etiology.
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